Cargando…
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. The majority of patients with endometrial cancer have an early disease and favorable prognosis; however, a significant proportion of endometrial cancer, which mainly comprises high-gra...
Autores principales: | Saito, Ayumi, Yoshida, Hiroshi, Nishikawa, Tadaaki, Yonemori, Kan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546653/ https://www.ncbi.nlm.nih.gov/pubmed/34733610 http://dx.doi.org/10.5306/wjco.v12.i10.868 |
Ejemplares similares
-
Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004) -
Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004) -
Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer
por: Valenzuela, Guillermo, et al.
Publicado: (2022) -
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
por: Abunada, Aya, et al.
Publicado: (2023) -
Epidermal growth factor signalling and bone metastasis
por: Lu, X, et al.
Publicado: (2010)